Anthony Boitano

USPTO Granted Patents = 14 (Patent Applications = 35)

EPO Patents = 1 (Patent Applications = 35)

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 6(Granted Patents)

Company Filing History:

7 out of 14

Magenta Therapeutics, Inc.

Heidelberg Pharma Research Gmbh

patents

4. 1 out of 77

Crispr Therapeutics Ag

patents

Years Active: 2018-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12403200 - Methods and compositions for treating autoimmune diseases (2025-09-02),

2. 12403185 - Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy (2025-09-02),

3. 12291576 - Anti-CD45 antibodies and conjugates thereof (2025-05-06),

4. 12251448 - Compositions and methods for the depletion of CD5+ cells (2025-03-18),

5. 12209135 - Anti-CD45 antibodies and conjugates thereof (2025-01-28),

6. 12006370 - Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy (2024-06-11),

7. 11958908 - Compositions and methods for the depletion of CD117+ cells (2024-04-16),

8. 11572411 - Anti-CD117 antibodies and conjugates (2023-02-07),

9. 11260079 - Dosing regimens for the mobilization of hematopoietic stem and progenitor cells (2022-03-01),

10. 10899843 - Compositions and methods for the depletion of CD117+ cells (2021-01-26),

11. 10882915 - Compositions and methods for the depletion of CD117+ cells (2021-01-05),

12. 10576161 - Compositions and methods for the depletion of CD137+ cells (2020-03-03),

13. 10434185 - Compositions and methods for the depletion of CD137+ cells (2019-10-08),

14. 10058573 - Dosing regimens for the mobilization of hematopoietic stem cells (2018-08-28),

Title: The Innovative Contributions of Anthony Boitano in Biomedicine

Introduction

Anthony Boitano, a prolific inventor located in Newton, MA, is renowned for his innovative contributions to the field of biomedicine. With 12 patents to his name, Boitano has focused on developing groundbreaking therapeutics that target specific cells for the treatment of various diseases. His latest patents showcase his dedication to advancing medical science and improving patient outcomes.

Latest Patents

Among his most recent innovations are the patents for Anti-CD45 antibodies and their conjugates. These inventions involve the use of antibodies that target CD45 expressing hematopoietic stem cells or immune cells prior to transplantation, which holds promise for enhancing transplant success rates. Another significant patent is for compositions and methods aimed at depleting CD5+ cells. This invention offers therapeutic solutions for treating stem cell disorders, cancers, and autoimmune diseases by eradicating harmful CD5+ cancer cells and autoreactive immune cells.

Career Highlights

Throughout his career, Anthony Boitano has contributed significantly to several companies, including Magenta Therapeutics, Inc. and Vor Biopharma Inc. His extensive research and development efforts have placed him at the forefront of innovation in the biomedical sector, driving forward new treatments and enhancing the understanding of complex conditions.

Collaborations

In his journey, Boitano has collaborated with notable industry professionals such as Rahul Palchaudhuri and Bradley R Pearse. These partnerships have allowed him to synergize his expertise with other innovators, further amplifying the impact of his work in the scientific community.

Conclusion

Anthony Boitano stands out as a key figure in the field of biomedical innovation. His commitment to research and discovery, along with his impressive portfolio of patents, reflects his leadership in developing therapies that have the potential to transform patient care. As he continues to push the boundaries of science, Boitano's work serves as an inspiration for future innovators in the biomedical field.

This text is generated by artificial intelligence and may not be accurate.